Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826965 · ClinicalTrials.gov registry record · NA
VAC Bioburden Wound Care Assessment
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT04826965: Clinical Trial NA study, sponsored by Duke University.
NCT04826965 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04826965, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the microbiologic burden and need for further operative debridement of patients undergoing primary surgical debridement of infected tissue, soft tissue abscesses, or traumatic wounds of the upper and lower extremity.
Primary Outcome
Bacterial bio-burden as measured by microbial PCR prior to debridement using the MicroGen PCR platform (DBA Microgen Diagnostics, LLC, Lubbock, TX). Reported as the number of participants with low (\< 1x10\^5), medium (1x10\^5 to 1x10\^7), and high (\> 1x10\^7) counts of bacteria per gram.
Interventions
- DEVICE Wound Vac is applied
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2022-10-13 |
| Phase | NA |
Why NCT04826965 stopped before completion
NCT04826965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Wound Vac is applied is the first listed.
NCT04826965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04826965 about?
NCT04826965 is a clinical study titled "VAC Bioburden Wound Care Assessment". The purpose of this study is to compare the microbiologic burden and need for further operative debridement of patients undergoing primary surgical debridement of infected tissue, soft tissue abscesses, or traumatic wounds of the upper and lower extremity.
What is the current status of trial NCT04826965?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2021-08-01. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT04826965?
The interventions under investigation include: Wound Vac is applied (DEVICE).
Who is sponsoring clinical trial NCT04826965?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04826965's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI